DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2) ) Antagonist - Pipeline Insight, 2020

Publisher Name :
Date: 03-Jul-2020
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

Overview

"DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist - Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist pipeline landscape is provided, which includes the topic Overview

and DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist mechanism of action. The assessment part of the report embraces, in-depth DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes the product description, mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist pipeline development activities

The report provides insights into:

- All the companies developing therapies of DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist with aggregate therapies developed by each company for the same.

- Different therapeutic candidates in early-stage, mid-stage and late stage of development for DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist.

- Key players involved in DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

- Collaborations (company-company collaborations and company-academia collaborations), licensing agreements and financing details for future developments of DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third party sources, etc.

DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Analytical Perspective by DelveInsight

- In-depth DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Commercial Assessment of products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, acquisition deal value trends. The sub-segmentation is described in the report, which provides company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form.

- DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this mechanism of action.

Scope of the report

- The DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist report provides an Overview

of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA the complete product development cycle, including all clinical and nonclinical stages.

- It comprises of detailed profiles of DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist therapeutic products with key coverage of involved technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

- Elucidated DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist research and development progress and trial details, results wherever available, are also included in the pipeline study.

- Coverage of dormant and discontinued pipeline projects along with the reasons if available across DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist.

Report highlights

- In the coming years, the DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist market is set to change due to the extensive research in this filed, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

- The companies and academics are working to assess challenges and seek opportunities that could influence DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

- There are several companies involved in developing therapies for DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist. Launch of emerging therapies of DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist will significantly impact the market.

- A better understanding of the target mechanism will also contribute to the development of novel therapeutics for DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist.

- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions

- What are the current treatment options available based on the DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist?

- How many companies are developing therapies by working on DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist?

- What are the principal therapies developed by these companies in the industry?

- How many therapies are developed by each company for DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist to treat disease condition?

- How many emerging therapies are in early-stage, mid-stage, and late stage of development for DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist?

- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist therapies?

- Which are the dormant and discontinued products and the reasons for the same?

- What is the unmet need for current therapies developed based on this mechanism of action?

- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist and their status?

- What are the results of the clinical studies and their safety and efficacy?

- What are the key designations that have been granted for the emerging therapies for DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist?

- How many patents are granted and pending for the emerging therapies of DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist?

DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2) ) Antagonist - Pipeline Insight, 2020

Table of Contents

1. Report Introduction
2. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist
2.1. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Overview
2.2. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Classification
2.3. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Structure
2.4. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Mechanism of Action
2.5. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Application
3. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist - DelveInsight's Analytical Perspective
3.1. In-depth Commercial Assessment
3.1.1. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist companies collaborations, Licensing, Acquisition Deal Value Trends
3.1.1.1. Assessment Summary
3.1.2. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Collaboration Deals
3.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis
3.1.2.2. Company-University Collaborations (Licensing/Partnering) Analysis
3.1.2.3. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Acquisition Analysis
4. Therapeutic Assessment
4.1. Clinical Assessment of Pipeline Drugs
4.1.1. Assessment by Phase of Development
4.1.2. Assessment by Product Type (Mono/Combination)
4.1.2.1. Assessment by Stage and Product Type
4.1.3. Assessment by Route of Administration
4.1.3.1. Assessment by Stage and Route of Administration
4.1.4. Assessment by Molecule Type
4.1.4.1. Assessment by Stage and Molecule Type
4.1.5. Assessment by MOA
4.1.5.1. Assessment by Stage and MOA
4.1.6. Assessment by Target
4.1.6.1. Assessment by Stage and Target
5. Late Stage Products (Phase-III)
6. Mid Stage Products (Phase-II)
7. Early Stage Products (Phase-I)
8. Pre-clinical Products and Discovery Stage Products
9. Inactive Products
10. Dormant Products
11. Discontinued Products
12. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Product Profiles
12.1. Drug Name: Company
12.1.1. Product Description
12.1.1.1. Product Overview
12.1.1.2. Mechanism of action
12.1.2. Research and Development
12.1.2.1. Clinical Studies
12.1.3. Product Development Activities
12.1.3.1. Collaboration
12.1.3.2. Agreements
12.1.3.3. Acquisition
12.1.3.4. Patent Detail
12.1.4. Tabulated Product Summary
12.1.4.1. General Description Table
Detailed information in the report
13. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Key Companies
14. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Key Products
15. Dormant and Discontinued Products
15.1. Dormant Products
15.1.1. Reasons for being dormant
15.2. Discontinued Products
15.2.1. Reasons for the discontinuation
16. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist - Unmet Needs
17. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist - Future Perspectives
18. DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Analyst Review
19. Appendix
20. Report Methodology
20.1. Secondary Research
20.2. Expert Panel Validation

List of Tables

Table 1 : Assessment Summary
Table 2 : Company-Company Collaborations (Licensing/Partnering) Analysis
Table 3 : DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Acquisition Analysis
Table 4 : Assessment by Phase of Development
Table 5 : Assessment by Product Type (Mono/Combination)
Table 6 : Assessment by Stage and Product Type
Table 7 : Assessment by Route of Administration
Table 8 : Assessment by Stage and Route of Administration
Table 9 : Assessment by Molecule Type
Table 10 : Assessment by Stage and Molecule Type
Table 11 : Assessment by MOA
Table 12 : Assessment by Stage and MOA
Table 13 : Assessment by Target
Table 14 : Assessment by Stage and Target
Table 15 : Late Stage Products (Phase-III)
Table 16 : Mid Stage Products (Phase-II)
Table 17 : Early Stage Products (Phase-I)
Table 18 : Pre-clinical and Discovery Stage Products
Table 19 : Inactive Products
Table 20 : Dormant Products
Table 21 : Discontinued Products

List of Figures

Figure 1 : Structure
Figure 2 : Mechanism
Figure 3 : DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist companies collaborations, Licensing, Acquisition Deal Value Trends
Figure 4 : Company-Company Collaborations (Licensing/Partnering) Analysis
Figure 5 : DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist Acquisition Analysis
Figure 6 : Assessment by Phase of Development
Figure 7 : Assessment by Product Type (Mono/Combination)
Figure 8 : Assessment by Stage and Product Type
Figure 9 : Assessment by Route of Administration
Figure 10 : Assessment by Stage and Route of Administration
Figure 11 : Assessment by Molecule Type
Figure 12 : Assessment by Stage and Molecule Type
Figure 13 : Assessment by MOA
Figure 14 : Assessment by Stage and MOA
Figure 15 : Late Stage Products (Phase-III)
Figure 16 : Mid Stage Products (Phase-II)
Figure 17 : Early Stage Products (Phase-I)
Figure 18 : Pre-clinical and Discovery Stage Products
Figure 19 : Inactive Products
Figure 20 : Dormant Products
Figure 21 : Discontinued Products
Figure 22 : Unmet Needs
  • Global Gelling Fiber Wound Dressings Market Growth 2020-2025
    Published: 19-Oct-2020        Price: US 3660 Onwards        Pages: 165
    According to this study, over the next five years the Gelling Fiber Wound Dressings market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Gelling Fiber Wound Dressings business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Gelling Fiber......
  • Global Betamethasone API Market Growth 2020-2025
    Published: 19-Oct-2020        Price: US 3660 Onwards        Pages: 158
    According to this study, over the next five years the Betamethasone API market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Betamethasone API business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Betamethasone API market by product t......
  • Global Prednisone API Market Growth 2020-2025
    Published: 19-Oct-2020        Price: US 3660 Onwards        Pages: 166
    According to this study, over the next five years the Prednisone API market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Prednisone API business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Prednisone API market by product type, appl......
  • Global Prednisone Acetate API Market Growth 2020-2025
    Published: 19-Oct-2020        Price: US 3660 Onwards        Pages: 167
    According to this study, over the next five years the Prednisone Acetate API market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Prednisone Acetate API business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Prednisone Acetate API mark......
  • Global Dexamethasone API Market Growth 2020-2025
    Published: 19-Oct-2020        Price: US 3660 Onwards        Pages: 164
    According to this study, over the next five years the Dexamethasone API market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Dexamethasone API business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Dexamethasone API market by product t......
  • Global Cytokine Release Syndrome Treatment Market Growth 2020-2025
    Published: 19-Oct-2020        Price: US 3660 Onwards        Pages: 134
    According to this study, over the next five years the Cytokine Release Syndrome Treatment market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Cytokine Release Syndrome Treatment business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of C......
  • Global Cytokine Storm Market Growth 2020-2025
    Published: 19-Oct-2020        Price: US 3660 Onwards        Pages: 133
    According to this study, over the next five years the Cytokine Storm market will register a XX%% CAGR in terms of revenue, the global market size will reach $ XX million by 2025, from $ XX million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Cytokine Storm business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Cytokine Storm market by product type, appl......
  • COVID-19 World Thioctic Acid (Alpha Lipoic Acid) Market Research Report (by Product Type, End-User / Application and Regions / Countries)
    Published: 18-Oct-2020        Price: US 2800 Onwards        Pages: 102
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. The report includes as follows: The report provides current data, historical overview and future forecast. The report includes an in-depth analysis of the Global market for Thioctic Acid (Alpha Lipoic Acid) , cove......
  • COVID-19 World Soft Gelatin Capsules Market Research Report (by Product Type, End-User / Application and Regions / Countries)
    Published: 18-Oct-2020        Price: US 2800 Onwards        Pages: 117
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. The report includes as follows: The report provides current data, historical overview and future forecast. The report includes an in-depth analysis of the Global market for Soft Gelatin Capsules , covering Global ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs